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Abstract Adenosine monophosphate-activated protein kinase
(AMPK) acts as a fuel gauge that maintains energy homeostasis
in both normal and cancerous cells, and has emerged as a tumor
suppressor. The present study aims to delineate the functional
relationship between AMPK and transforming growth factor
beta (TGF-β). Our results showed that expression of liver ki-
nase B1 (LKB1), an upstream kinase of AMPK, impeded
TGF-β-induced Smad phosphorylation and their transcriptional
activity in breast cancer cells, whereas knockdown of LKB1 or
AMPKα1 subunit by short hairpin RNA (shRNA) enhanced
the effect of TGF-β. Furthermore, AMPK activation reduced
the promoter activity of TGF-β1. In accordance, type 2 diabetic
patients taking metformin displayed a trend of reduction of
serum TGF-β1, as compared with those without metformin.
A significant reduction of serum TGF-β1 was found in mice
after treatment with metformin. These results suggest that
AMPK inhibits the transcription of TGF-β1, leading to reduc-
tion of its concentration in serum. Finally, metformin sup-
pressed epithelial-to-mesenchymal transition of mammary epi-
thelial cells. Taken together, our study demonstrates that AMPK
exerts multiple actions on TGF-β signaling and supports that
AMPK can serve as a therapeutic drug target for breast cancer.
Keywords LKB1 . AMPK . TGF-β production and
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Introduction
Adenosine monophosphate-activated protein kinase (AMPK)
acts as a fuel-sensing enzyme that plays an important role in
regulating energy metabolism in both normal and malignant
cells. Furthermore, it has emerged as a tumor suppressor that
mediates the tumor-suppressive function of liver kinase B1
(LKB1) [1, 2]. A plethora of studies have demonstrated that
AMPK regulates a broad spectrum of factors involved in cell
metabolism, proliferation, survival, migration, and invasion [3].
Interestingly, a seminal retrospective investigation has reported
that the incidence of cancer is significantly reduced in patients
with type 2 diabetes receivingmetformin, anAMPK activator, as
a glucose-lowering drug [4]. Afterwards, several clinical studies
have demonstrated that expression of LKB1 orAMPKactivity is
reduced in advanced breast cancer [5, 6]. The alteration is asso-
ciated with histological grades, metastasis, and poor prognosis.
Intriguingly, studies have compared the complete pathological
response or distant metastasis in diabetic patients complicated
with breast cancer who received metformin in neoadjuvant che-
motherapy to those without it [7]. The results have shown that
metformin causes a higher complete pathological response rate
and that the patients not taking metformin have a trend to distant
metastasis. Therefore, these clinical studies suggest that AMPK
may be a therapeutic target for breast cancer progression.
The transforming growth factor beta (TGF-β) family regu-
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differentiation, adhesion, migration, and apoptosis, which are
involved in both physiological and pathophysiological pro-
cesses [8]. While TGF-β exerts a suppressive effect in early
stages of tumorigenesis, hence regarded as a tumor suppressor,
it promotes tumor progression and metastasis in late stages [8].
In fact, many studies have shown that serum levels of TGF-β
increase in breast cancer and other cancers and can serve as a
predictive and prognostic marker of cancer stage [8–11]. Thus,
persistently high circulating TGF-β levels after curative re-
moval of primary tumor predicts early metastatic recurrence
in distant organs while its decrease correlates with response
to treatment [12]. Increased secretion of TGF-β from tumors
renders them more resistant to chemotherapy, whereas antag-
onizing TGF-β with neutralizing antibody or inhibitors can
increase the chemotherapeutic sensitivity of tumor cells
[13–16]. The activation of the TGF-β signaling pathway pro-
motes metastasis of cancer via complex mechanisms, one of
which is to regulate epithelial-to-mesenchymal transition
(EMT), a critical step for cancer stem cell (CSC) transition
and cancer metastasis [17].
In recent years, many studies have shown that AMPKplays
an inhibitory role in EMT, tissue fibrosis, and malignant trans-
formation [18–25]. However, mechanisms underlying EMT
are complex involving multiple factors and pathways. The
negative regulation impinged upon TGF-β constitutes one of
the mechanisms. With regards to the effect on TGF-β signal-
ing, it has been reported that this could occur through inhibi-
tion of Smad2/3 phosphorylation or a Smad3-dependent but
phosphorylation-independent event [26, 27]. In exploring the
molecular link between AMPK and progression of breast
cancer, the present study investigated the effect of AMPK
activation on TGF-β signaling. Our results showed that
AMPK activation suppressed TGF-β-induced phosphoryla-
tion of Smad2/3 phosphorylation in MDA-MB-231 cells
and MCF10A cells. Knockdown of LKB1 and AMPKα1
by short hairpin RNA (shRNA) disrupted acinus formation
and enhanced responses of the cells to TGF-β in terms of
Smad2/3 phosphorylation and promoter activity. Furthermore,
our data showed that metformin reduced serum TGF-β1 levels
in type 2 diabetic patients and mice. In keeping with this,
metformin inhibited the transcriptional activity of TGF-β1
promoter. Finally, AMPK activation attenuates EMT induced
by TGF-β1. Altogether, our results demonstrate that AMPK
inhibits TGF-β signaling via multiple mechanisms.
Materials and methods
Ethical statement for human serum collection
The study using human serum samples was approved by the
Human Study Ethics Committee of The First Affiliated Hos-
pital of Nanchang University (Nanchang, China). Sera were
collected from patients with type 2 diabetes who were treated
with metformin (10 males and 11 females) or with other
glucose-lowering drugs (15 males and 14 females) in the out-
patient clinic. The age of patients ranged from 45 to 65 years.
Blood samples were obtained under the consent of patients.
Reagents
Metformin and phenformin were purchased from Sigma-
Aldrich (St. Louis, MO, USA); human TGF-β1 and antibodies
against β-actin, p-AMPKα Thr172, AMPKα, p-ACC Ser79,
ACC, Slug, p-Smad3 Ser423/425, and Smad2/3 were from
Cell Signaling Technology (Beverly, MA, USA); ELISA kits
for human and mouse TGF-β1, antibodies against E-cadherin,
and vimentin were from Abcam (Cambridge, MA, USA);
monoclonal antibody against LKB1 was from Santa Cruz Bio-
technology (Santa Cruz, CA, USA); growth factor-reduced
Matrigel and monoclonal antibody against β-catenin were
from BD Biosciences (San Jose, CA, USA); Lipofectamine
2000, 4′,6-diamidino-2-phenylindole (DAPI), fluorescein iso-
thiocyanate (FITC)-conjugated donkey anti-rabbit antibodies
were fromLife Technologies (Grand Island,NE, USA); Cham-
ber slides was from EMD Millipore (Billerica, MA, USA).
Animal study
Animal protocol was approved by the Institutional Animal
Ethics Committee of The First Hospital of Nanchang Univer-
sity. BALB/c mice (6 weeks old) were provided by the Animal
Core Laboratory of Jiangxi Medical College, Nanchang Uni-
versity. The blood (0.2ml) was collected from the orbital sinus
after inhaling anesthetization with isoflurane, and the serum
was separated and stored at −80 °C prior to use. Animals were
injected with metformin (100 mg/kg/day) i.p. for 1 w and
euthanized by carbon dioxide, immediately followed by car-
diac injection for blood collection. Sera were used for mea-
surement of TGF-β1.
Cell culture, transfection, and virus infection
MDA-MB-231 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10 % fetal
bovine serum (FBS) and NMuMG cells in DMEM sup-
plemented with 10 % FBS and insulin (10 μg/ml) at 5 %
CO2 and 37 °C. MCF10A cells were cultured in DMEM/F12
cells supplemented with 5 % horse serum, EGF (20 ng/ml),
insulin (10 μg/ml), hydrocortisone (0.5 mg/ml), and cholera
toxin (100 ng/ml). All the media were supplemented with
penicillin/streptomycin (Pen/Strep) solution.
For transient expression, mammalian expression plasmids
containing genes of interest were transfected into appropriate
cells using Lipofectamine 2000. Forty-eight hours post-
8250 Tumor Biol. (2016) 37:8249–8258
transfection, the cells were treated with agents as indicated in
the figure legend and lysed with appropriate solutions.
For virus infection, lentivirus encoding shRNAs for green
fluorescent protein (GFP) and LKB1 (gift from Bin Zheng,
Massachusetts General Hospital) was packaged in 293 T cells
and the virus supernatant was infected into MCF10A cells.
Lentivirus for AMPKα1 shRNAwas purchased from Sigma-
Aldrich and infected into MCF10A cells. Two days after in-
fection, the cells were selected with puromycin (1 μg/ml)
Three-dimensional cell culture
Analysis of acinar structure was carried out as described pre-
viously [28]. Briefly, growth factor-reduced Matrigel was
allowed to thaw out on ice and 40 μl was added to each well
of chamber slides, which was placed to tissue culture incuba-
tor to solidify Matrigel. MCF10A cells were trypsinized, re-
suspended in DMEM/F12 containing 20 % horse serum, and
then centrifuged and resuspended again in assay media
(DMEM/F12, insulin [10 μg/ml], hydrocortisone [0.5 μg/ml],
cholera toxin [100 ng/ml], 2 % horse serum, Pen/Strep). The
cell density was adjusted to 5000 cells/400 μl in the assay
media supplemented with 2.5 % Matrigel and 5 ng/ml EGF,
and the cells were overlayed on the top of a Matrigel chamber.
The medium was changed every 4 days until 10∼14 days.
When cells formed clumps under a light microscope, the
chamber slides were fixed with 5 % formalin at room temper-
ature for 30 min, washed with phosphate-buffered saline
(PBS), and permeabilized with 0.5 % Triton X-100 in PBS
for 5 min, washed again, blocked, and subsequently incubated
with first antibody, FITC-conjugated second antibody, and
DAPI.
Immunofluorescent cytochemistry
Immunofluorescent labeling of cells was conducted following
the provider’s protocol for FITC-conjugated antibody
(Life Technologies, Grand Island, NE, USA). Briefly,
the cells were plated onto coverslips pre-coated with
0.01 % polylysine. After treatment, the cells were fixed
with 4 % paraformaldehyde for 30 min, permeabilized
in PBS-0.3 % Triton X-100 for 5 min, and incubated in a PBS
and 1 % bovine serum albumin (BSA) blocking solution for
1 h. The cells were incubated with anti-E-cadherin at 4 °C
overnight and stained with FITC-conjugated secondary anti-
body at room temperature for 1 h. Cell nuclei were counter-
stained with DAPI. All the images were taken under a fluo-
rescent microscope (Nikon C2).
Western blot analysis
Cells were stimulated with TGF-β1 (5 ng/ml) and metformin
(10 mM). Protein concentration was determined using a
Coomassie brilliant blue staining method. An equal amount
of protein (20∼25μg) was separated on SDS-PAGE and trans-
ferred to nitrocellulose membranes. The membranes were
blocked in 5 % nonfat milk prepared in Tris-buffered saline-
0.1 % Tween 20 (TBST) at room temperature for 1 h and then
incubated with primary antibody in 2 % BSA-TBST at 4 °C
from 2 h to overnight. The membranes were washed
and incubated with HRP-conjugated secondary antibody.
Immuno-reactive protein was detected using an ECL kit
(Bio-Rad, USA).
Luciferase assay
The promoter sequence of human TGF-β1 was selected
according to Kim et al. [29], and a 1.4-kb fragment am-
plified from genomic DNA was isolated from 293 T cells
by PCR using the following primers: forward primer, 5′
agctctcgag(XhoI)TTA GCA GGG GAG TAA CAT GGA
TTT3′, and reverse primer, agctaagctt (HindIII)AGG GAG
GTGGGAGGGAGATG3′ The DNA segment was digested
with XhoI andHindIII and then subcloned to the site upstream
of firefly luciferase in pGL3 plasmid (Promega, USA). The
insert was verified by sequencing analysis.
The plasmid encoding a firefly luciferase reporter where
a TGF-β1 promoter or Smad2/3 response element lies
upstream was co-transfected with the plasmid encoding
Renilla luciferase into cells using Lipofectamine 2000. After
48 h, the cells were treated with TGF-β and/or metformin for
8 h. Luciferase activity was determined using a Dual-Luciferase
Assay Kit (Promega, USA) and expressed as a ratio of firefly
luciferase to Renilla luciferase reading units.
Measurement of serum TGF-β1 level
Human and mouse serum TGF-β1 levels were measured
using ELISA kits from Abcam (Cambridge, USA), according
to the protocols provided by the manufacturer. Serum samples
were first activated by acidification and then neutralized and
diluted. Thus, the concentration reflected total TGF-β1.
RNA extraction and real-time PCR
Total RNA was extracted using a kit from Thermo Fisher
Scientific (Waltham, MA, USA) following the manufacturer’s
instructions. Two micrograms of total RNA was used for
cDNA synthesis. Real-time PCR was carried out for detection
of Twist and zinc finger E-box binding homeobox 1 (ZEB1)
using the SYBR Green PCR Master Mix 2× reagent in 20 μl
according to the protocol provided by the manufacturer
Applied Biosystems (Foster City, CA, USA). PCR was
run in triplicates and repeated for three times. Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used as a
control to normalize the variability in expression levels.
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Primer sequences for real-time PCR were the following:
Twist forward 5′-TGG ACA GAG ATT CCC AGA GG-3′,
reverse 5′- TTC CTG TCA GTG GCT GAT TG; ZEB1
forward 5′-AAG CAG CCA GAG AAG AGC TG-3′,
reverse 5′- CCACATCAACACTGGTCGTC; and GAPDH
forward 5′- CAT CTT CCA GGA GCG AGA CC-3′, reverse
5′- CTC GTG GTT CAC ACC CAT C-3′.
Wound healing assay
Cell monolayers were scratched with a plastic tip. After treat-
ment, the migration was followed at 37 °C for 24 h and
photographed at the beginning and end of experiment using
a Live Cell Imaging System (Olympus IX2-VCB, Tokyo) at
×40 magnification. The migration distance was calculated
using ImageJ software.
Transwell assay
NMuMG cells were treated with TGF-β1 for 36 h, 2×105
cells in the 0.2 % FBS medium were plated into the upper
chamber with 8-μm pores (Corning; Life Sciences, MA,
USA), and DMEM containing 10 % FBS was placed in the
lower chamber. Cells were treated with metformin (10 mM) in
the upper chamber and TGF-β1 (5 ng/ml) in the lower cham-
ber. After 24 h, the filters were fixed in methanol for 10 min
and stained with 0.1 % crystal violet (Solabri, Beijing) for
12 min. Randomly selected fields were photographed under
a microscope, and stained cells were statistically analyzed.
Statistical analysis
Data are presented as mean±SD. Significance of differences
between groups was tested using Student’s t test (p<0.05).
Results
LKB1/AMPK inhibits Smad phosphorylation induced
by TGF-β
To examine if LKB1 and AMPK inhibit the function of
TGF-β in breast cancerous or precancerous cells, we made
stable cell lines by silencing AMPKα1 and LKB1 by shRNA
in MCF10A cells and transfecting LKB1 into MDA-MB-231
cells.We first assessed if silencing AMPK and LKB1 promoted
cell proliferation or decreased apoptosis of MCF10A cells, an
immortalized human mammary epithelial cell line. Our results
showed that the doubling time was decreased (data not shown).
We then utilizedMatrigel to observe acinus formation and com-
pared the ability of the cells bearing GFP shRNA, LKB1
shRNA, andα1 shRNA to form an acinar structure, a parameter
of mammary epithelial cell transformation. As shown in Fig. 1,
2 weeks after plating onMatrigel,MCF10A cells formed acinus
while the cells with LKB1 or α1 subunit of AMPK silenced
failed to do so, suggesting that LKB1/AMPK could inhibit the
transformation of mammary epithelial cells. Unfortunately, we
could not show the effect of metformin and TGF-β in this
setting, as both inhibited the growth of MCF10A cells on
Matrigel, where cell clumps became very small. Next, we
assessed the effects of metformin on TGF-β-induced Smad
phosphorylation in cultured cells. First, our data showed that
metformin suppressed the phosphorylation of Smad2/3 induced
by TGF-β (Fig. 2a). Second, knockdown of LKB1 and
AMPKα1 made the cells more sensitive to TGF-β (Fig. 2b).
In contrast, overexpression of LKB1 in MDA-MB-231 cells
blunted the Smad2/3 phosphorylation (Fig. 2c).
To ascertain if the reduction of Smad phosphorylation re-
sulted in an inhibition of their transcription activity, we con-
ducted luciferase reporter assays. Thus, we transfected plas-
mid containing firefly luciferase regulated by Smad2/3 re-
sponse elements and then assessed the responses of MCF10A
cells and MDA-MB-231 cells to metformin and TGF-β. As
shown in Fig. 3, TGF-β stimulated the promoter activity
(Fig. 3a, p<0.01), which was offset by co-treatment with met-
formin (Fig. 3a, p<0.01). A similar result was obtained with
MDA-MB-231 cells (Fig. 3c). When MCF10A cells with
LKB1 silenced were used, the luciferase activity was found
as high as that in control cells treated with TGF-β (Fig. 3b,
p<0.01) and further increased by TGF-β (Fig. 3b, p<0.01).
Collectively, these results clearly demonstrated that metformin
and LKB1 inhibited the effect of TGF-β on phosphorylation
of Smad2/3, leading to suppression of its transcription activity
in breast cancer cells and in precancerous lesion.
Metformin suppresses production of TGF-β1
We were curious at the regulation of TGF-β1 expression by
metformin. Thus, we cloned genomic DNA encompassing
1.4 kb that covers an essential promoter sequence of
TGF-β1 and placed this sequence upstream of the luciferase
gene. When this plasmid was transfected into MDA-MB-231
cells and treated with metformin or phenformin, the promoter
activity was reduced by about 50 % (p<0.01) (Fig. 4a). We
then went on investigating the effect of metformin on serum
levels of TGF-β1. First, we collected the sera of patients with
type 2 diabetes from the outpatient clinic. Among them, one
group was treated only with metformin and another age-
matched group was treated with other glucose-lowering drugs
but without metformin. We assayed TGF-β1 levels and found
that patients with metformin treatment displayed reduced se-
rum concentration of TGF-β1 but this change was not signif-
icant (p>0.05), probably due to an insufficient number of
patients (Fig. 4b). Next, we carried out the assay in mice,
where the sera were collected before and after treatment with
metformin for 1 week and TGF-β1 was measured. The result
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revealed that serum levels of TGF-β1 were significantly re-
duced (p<0.05) (Fig. 4c). Thus, our results revealed a new
role of AMPK in TGF-β1 production.
Metformin inhibits mouse EMT induced by TGF-β
In this study, we attempted to use mouse NMuMG cells, as
they appeared to be a better cell model in our hands. When
NMuMG cells were treated with TGF-β1 for 48 h, mor-
phological changes toward mesenchymal cells were easily
achieved, accompanied with a decrease in E-cadherin and
increases in N-cadherin, β-catenin, vimentin, and Slug (Fig. 5).
To assess the effect of metformin on EMT, we tested the
ability of metformin to activate AMPK in NMuMG cells and
found that AMPK was activated well by metformin (Fig. 6a).
Then, we treated the cells with TGF-β1 alone or together with
metformin or 5-amino-4-imidazolecarboxamide riboside
(AICAR) for 48 h. Our results showed that the stimulatory
effects of TGF-β1 on mesenchymal markers were abrogated
by metformin or AICAR (Fig. 6b–d). Since EMT often
acquires accelerated cell migration, we assessed if the
stimulation of cell migration by TGF-β1 was suppressed
by metformin. Our data revealed that TGF-β stimulated
the migration of NMuMG cells on transwell and would
healing assays, which were significantly inhibited bymetformin
(Fig. 7). Taken together, our results showed that TGF-β stimu-
lated EMT and migration of NMuMG cells, all of which were
compromised byAMPK activation (i.e., metformin or AICAR),
underpinning an inhibitory role of AMPK.
Discussion
TGF-β plays a tumor-suppressing role in early stages of
tumorigenesis but a promoting role in tumor progression
in late stages. Thus, activation of this signaling pathway
Fig. 1 LKB1 and AMPK regulate cell viability. MCF10A cells were
infected with lentivirus expressing shRNAs for LKB1, AMPKα1, or
GFP. The cells with shRNAs were overlayed on Matrigel bed and
cultured for 2 weeks. The mammary cell clusters on the culture
chamber were fixed and stained with anti-E-cadherin antibody
followed by FITC-conjugated second antibody and DAPI staining.
Photos were taken under a fluorescent microscope at ×20 magnification.
Representative images are presented. a Superimposed image of FITC and
DAPI staining. b DAPI staining of the acinus derived from GFP shRNA
cells. c DAPI staining of α1 shRNA cells. d DAPI staining of LKB1
shRNA cells
Fig. 2 LKB1 inhibits TGF-β-induced Smad2/3 phosphorylation. a
MCF10A cells were treated with or without metformin (5 mM) for 8 h,
followed by TGF-β1 for indicated time. b MCF10A cells containing
different shRNAs were treated with TGF-β1 for indicated time. c
MDA-MB-231 cells stably transfected with LKB1 or empty vector as a
control were treated with TGF-β1 (5 ng/ml) for different time periods.
Equal amounts (20 μg) of cell extracts were immunoblotted with
antibodies, as indicated
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delays the growth of primary tumor but enhances tumor
metastasis [30]. In recent years, regulation of TGF-β sig-
naling by AMPK has emerged as an important topic in
cancer biology because of their opposite roles in cancer
metastasis, EMT, and fibrosis [18–25]. In the present
study, we have shown that LKB1/AMPK possesses an
inhibitory role in TGF-β signaling. Thus, the presence or
overexpression of LKB1 diminished the responses of
breast cancer cells and precancerous mammary epithelial
cells to TGF-β, leading to reduced phosphorylation of
Smad2/3 and its transcription activity, whereas knockdown
of LKB1 and AMPKα1 resulted in opposite changes and
disruption of the acinus structure derived from mammary
epithelial cells. Interestingly, our results revealed that met-
formin and phenformin suppressed the promoter activity of
TGF-β1. In keeping with this, TGF-β1 levels in the sera
of patients with type 2 diabetes who received metformin
exhibited a trend of reduction, as compared with those
without metformin. Furthermore, they were significantly
reduced in the sera of mice that were administered with
metformin for a week. Finally, our data showed that
activation of AMPK inhibited TGF-β1-mediated EMT.
Hence, our study supports that AMPK could be a suitable
drug target to correct the pathophysiology of diseases en-
gendered by dysregulated TGF-β.
Three-dimensional culture on Matrigel has been used to
assess dysregulated proliferation and reduced apoptosis of
mammary epithelial cells [28]. Normal epithelial cells under-
go apoptosis in the middle of mammary cell cluster and result
in a hollow structure like acinus, while transformed cells are
resistant to apoptosis and thus cannot form acinus. In this
study, we found that knockdown of LKB1 and AMPK
disturbed the acinar structure, suggesting that LKB1/AMPK
inhibits cell growth and/or induces apoptosis in the area of
crowded cell clumps, which is in line with our previous
finding [31].
It has been shown that AMPK activated by a variety
of maneuvers, such as pharmacological activators or ac-
tivating mutation, inhibits TGF-β -mediated cellular
events. Until now, studies have suggested that mainly
three mechanisms account for AMPK inhibition of the
TGF-β signal transduction pathway: (1) Smad3-
Fig. 3 Inhibition of Smad2/3 transcriptional activity by LKB1/AMPK.
The TGF-β reporter plasmid encoding firefly luciferase driven by Smad-
responsive elements was co-transfected with Renilla luciferase into
MCF10A cells (a) or into MCF10A cells containing GFP or LKB1
shRNA (b). The cells were treated with TGF-β1 (TGF-β, 5 ng/ml) and/
or metformin (Met, 5 mM) for 8 h. Luciferase activity was assayed,
and the ratio of two luciferase activities is presented. Similar assays
were carried out in MDA-MB-231 cells (c). Statistical analysis was
performed using Student’s t test, and p values between groups are
indicated
Fig. 4 AMPK regulates TGF-β1 production. a The promoter region
(1.4 kb) was cloned upstream of firefly luciferase in pGL3 vector
(TGB1P) and the plasmid co-transfected with Renilla luciferase into
MDA-MB-231 cells. The cells were treated with metformin (Met.F,
5 mM) or phenformin (Phen.F, 1 mM) for 8 h. The luciferase assay
was performed as in Fig. 3. b Serum TGF-β1 levels from type 2
diabetic patients receiving metformin (Met) (n= 21) or non-metformin
(Non-Met) (n = 29) were measured using an ELISA kit. c Serum
TGF-β1 from mice (n = 10) before (Pre-Met) and after Met injec-
tion (i.p. 100 mg/kg/day) for 1 week was assayed. The mean with SEM
was presented as horizontal lines. Significance was tested using Student’s
t test. a **p< 0.01 (mean± SD, n= 5); b p > 0.05; c *p< 0.05
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dependent, but phosphorylation-independent [27] event; (2)
Smad3 phosphorylation-dependent [26] event; and (3)
p300-dependent event. In the third regulation, AMPK induces
degradation of p300, leading to decreased acetylation of
Smad3 and disruption of the complex between p300 and
Smad3 [19]. Our present study showed that AMPK sup-
pressed TGF-β-induced phosphorylation of Smad2/3, thereby
inhibiting its transcription activity. Furthermore, our study
adds an additional aspect of regulation in which AMPK sup-
presses the transcription and production of TGF-β1.
Fig. 5 Induction of EMT by
TGF-β. NMuMG cells were
incubated with TGF-β1 (5 ng/ml)
up to 48 h. The morphology of
EMTwas examined under a light
contrast microscope (a), by
indirect immunofluorescent
labeling of E-cadherin (FITC
labeled) and DAPI staining of the
nucleus (b) and by Western
blotting with antibodies against
EMT (c). Scan densitometry was
used to determine Western blot
signals of c from three
independent experiments and
plotted in d
Fig. 6 Metformin suppresses
induction of EMT markers in
NMuMG cells by TGF-β. a
NMuMG cells were treated with
metformin (10 mM) for different
time periods up to 12 h. b The
cells were treated with or without
AICAR (1 mM) ±TGF-β for
48 h. c The cells were treated with
or without metformin ±TGF-β
for 48 h. a–c Equal amounts of
cell extracts were immunoblotted
with antibodies, as indicated. d
The cells were treated as in c, total
RNAwas extracted, and real-time
PCRwas performed on ZEB1 and
Twist. The graph represents
averages normalized with
GAPDH in a triplicate experiment
(mean ± SD, n = 3). Statistical
analysis was performed using
Student’s t test, and p values
between groups are indicated
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Three TGF-β isoforms exist, β1, β2 and β3, which are
encoded by distinct genes and exhibit different expression
patterns and physiological and pathophysiological activities
in different cells and systems [32, 33]. The expression of
TGF-β is controlled by an auto-feed-back loop. The promoter
regions of TGF-β1 and TGF-β3 contain a Smad response
element such that the transcription is auto-regulated [32, 33].
In our study, we found that TGF-β1 was regulated by AMPK
at the transcription level but it is not clear if this occurs
through inhibition of Smad2/3 phosphorylation or an indepen-
dent event. In any case, it is an important finding in view of the
fact that TGF-β1 is upregulated in tissue fibrosis and ad-
vanced cancer.
A prior report showed that the serum level of TGF-β1 was
higher in type 2 diabetes than normal population but did not
find an effect of metformin [34]. A second study bymeasuring
serum levels of TGF-β1 in type 1 diabetes revealed that
TGF-β1 was elevated in the patients with retinopathy, sug-
gesting that it is involved in complications and can serve as a
progression marker for the disease [35]. Many studies have
reported elevation of TGF-β in advanced cancer [8–11]. In
our current study, we observed a decrease in the serum con-
centration of TGF-β1 in patients with type 2 diabetes treated
with metformin, as compared to non-metformin group, but it
was not significant. We are aware that our comparison may
need to be modified, as an appropriate comparison would be
made before and after treatment metformin. However, it is
difficult to conduct this sort of study, as TGF-β expression
levels may vary upon the disease stage and diabetic symptoms
may not be so severe to allow detection of the increase of
TGF-β at the beginning ofmetformin administration. To over-
come this obstacle, we will have to expand the sample size and
to carry out prospective studies on diabetic patients treated
with and without metformin for years. To rectify the flaws of
our human study, we treated mice with metformin for 1 week,
collected blood prior to and post treatment, and measured
serum TGF-β1 levels. Our results showed a significant reduc-
tion after treatment. Of note, the values of TGF-β1 levels in
our study were somewhat different from previously published
data [34–36]. This was probably caused by the use of different
methods. For example, some of these studies measured total
TGF-β (i.e., acidification of serum allows measurement of
bound and free TGF-β) while others assayed free TGF-β.
In the present study, we used a kit to measure total serum
TGF-β1.
In summary, we have shown that AMPK by activation of
metformin, AICAR, or LKB1 exerts a negative effect on
TGF-β signaling, leading to inhibition of Smad2/3 activation
Fig. 7 Metformin inhibits the ability of TGF-β to stimulate the migration
of NMuMG cells. a Migration through transwell membranes. NMuMG
cells (30,000/wells) were plated on the top of membranes, and the cells
were allowed to migrate for 24 h under the treatment, as indicated. The
migrated cells were stained with crystal violet, and the randomly selected
areas were photographed (left). Five randomly selected spots were
counted and plotted (right) with control as 100 %. b Wound healing
analysis. NMuMG cells were grown to confluence, scratched with a
pipette tip, and cultured for 24 h. The scratched areas were
photographed at 0 and 24 h. The migration rate was calculated
with ImageJ software. The graph represents values from three
independent experiments (mean ± SD). Statistical analysis was
performed using Student’s t test, and p values between groups are
indicated. Cont control, M+T metformin + TGF-β1
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and suppression of EMT and cell migration in breast cancer
cells and precancerous mammary epithelial cells. Interesting-
ly, we have shown that metformin inhibits transcription of
TGF-β1 and reduces serum levels of TGF-β1. Our next phase
of study will be to decipher the mechanism by which AMPK
regulates TGF-β1 transcription. In sum, our study supports
that AMPK could serve as a drug target in the treatment of
breast cancer progression as well as other disorders which are
aggravated by elevated TGF-β1.
AICAR 5-amino-4-imidazolecarboxamide riboside, AMP
adenosinemonophosphate,AMPK, AMP-activated protein ki-
nase, CSC cancer stem cell, EMT epithelial-to-mesenchymal
transition, GAPDH glyceraldehyde 3-phosphate dehydroge-
nase, LKB1 liver kinase B1, SNAIL1/2 transcription repressors
for E-cadherin, TGF-β transforming growth factor beta, ZEB1
zinc finger E-box binding homeobox 1
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